Ionis Pharmaceuticals projects 2026 revenue between $875M and $900M and targets over $3B peak sales for its drug TRYNGOLZA.
Ionis Pharmaceuticals outlined a 2026 revenue outlook of $875M to $900M during its Q2 2026 earnings call. The company also set a peak sales target exceeding $3B for its drug TRYNGOLZA, signaling confidence in its growth trajectory.
Management highlighted the company’s strong positioning for the second half of 2026, citing strategic opportunities ahead. The revenue projection follows recent milestones, though specific prior-year comparisons or consensus estimates were not detailed in the update.
No immediate market reaction was disclosed in the call insights.